New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
Abstract B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells within the tumor microenvironment. In addition to its immune checkpoint function, B7-H3 has been linked...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-023-01751-9 |
| _version_ | 1797865399079927808 |
|---|---|
| author | Ayechew Adera Getu Abiye Tigabu Ming Zhou Jianrong Lu Øystein Fodstad Ming Tan |
| author_facet | Ayechew Adera Getu Abiye Tigabu Ming Zhou Jianrong Lu Øystein Fodstad Ming Tan |
| author_sort | Ayechew Adera Getu |
| collection | DOAJ |
| description | Abstract B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells within the tumor microenvironment. In addition to its immune checkpoint function, B7-H3 has been linked to tumor cell proliferation, metastasis, and therapeutic resistance. Furthermore, its drastic difference in protein expression levels between normal and tumor tissues suggests that targeting B7-H3 with drugs would lead to cancer-specific toxicity, minimizing harm to healthy cells. These properties make B7-H3 a promising target for cancer therapy. Recently, important advances in B7-H3 research and drug development have been reported, and these new findings, including its involvement in cellular metabolic reprograming, cancer stem cell enrichment, senescence and obesity, have expanded our knowledge and understanding of this molecule, which is important in guiding future strategies for targeting B7-H3. In this review, we briefly discuss the biology and function of B7-H3 in cancer development. We emphasize more on the latest findings and their underlying mechanisms to reflect the new advances in B7-H3 research. In addition, we discuss the new improvements of B-H3 inhibitors in cancer drug development. |
| first_indexed | 2024-04-09T23:07:20Z |
| format | Article |
| id | doaj.art-548f0674a7c246f6a007edd897172c81 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-04-09T23:07:20Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-548f0674a7c246f6a007edd897172c812023-03-22T10:35:05ZengBMCMolecular Cancer1476-45982023-03-0122111510.1186/s12943-023-01751-9New frontiers in immune checkpoint B7-H3 (CD276) research and drug developmentAyechew Adera Getu0Abiye Tigabu1Ming Zhou2Jianrong Lu3Øystein Fodstad4Ming Tan5Institute of Biochemistry and Molecular Biology, Institute of Biomedical Sciences, and Research Center for Cancer Biology, China Medical UniversityInstitute of Biochemistry and Molecular Biology, Institute of Biomedical Sciences, and Research Center for Cancer Biology, China Medical UniversityCancer Research Institute and School of Basic Medical Sciences, Central South UniversityDepartment of Biochemistry and Molecular Biology, College of Medicine, University of FloridaDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital RadiumhospitaletInstitute of Biochemistry and Molecular Biology, Institute of Biomedical Sciences, and Research Center for Cancer Biology, China Medical UniversityAbstract B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells within the tumor microenvironment. In addition to its immune checkpoint function, B7-H3 has been linked to tumor cell proliferation, metastasis, and therapeutic resistance. Furthermore, its drastic difference in protein expression levels between normal and tumor tissues suggests that targeting B7-H3 with drugs would lead to cancer-specific toxicity, minimizing harm to healthy cells. These properties make B7-H3 a promising target for cancer therapy. Recently, important advances in B7-H3 research and drug development have been reported, and these new findings, including its involvement in cellular metabolic reprograming, cancer stem cell enrichment, senescence and obesity, have expanded our knowledge and understanding of this molecule, which is important in guiding future strategies for targeting B7-H3. In this review, we briefly discuss the biology and function of B7-H3 in cancer development. We emphasize more on the latest findings and their underlying mechanisms to reflect the new advances in B7-H3 research. In addition, we discuss the new improvements of B-H3 inhibitors in cancer drug development.https://doi.org/10.1186/s12943-023-01751-9B7-H3CD276CancerImmunotherapyDrug Development |
| spellingShingle | Ayechew Adera Getu Abiye Tigabu Ming Zhou Jianrong Lu Øystein Fodstad Ming Tan New frontiers in immune checkpoint B7-H3 (CD276) research and drug development Molecular Cancer B7-H3 CD276 Cancer Immunotherapy Drug Development |
| title | New frontiers in immune checkpoint B7-H3 (CD276) research and drug development |
| title_full | New frontiers in immune checkpoint B7-H3 (CD276) research and drug development |
| title_fullStr | New frontiers in immune checkpoint B7-H3 (CD276) research and drug development |
| title_full_unstemmed | New frontiers in immune checkpoint B7-H3 (CD276) research and drug development |
| title_short | New frontiers in immune checkpoint B7-H3 (CD276) research and drug development |
| title_sort | new frontiers in immune checkpoint b7 h3 cd276 research and drug development |
| topic | B7-H3 CD276 Cancer Immunotherapy Drug Development |
| url | https://doi.org/10.1186/s12943-023-01751-9 |
| work_keys_str_mv | AT ayechewaderagetu newfrontiersinimmunecheckpointb7h3cd276researchanddrugdevelopment AT abiyetigabu newfrontiersinimmunecheckpointb7h3cd276researchanddrugdevelopment AT mingzhou newfrontiersinimmunecheckpointb7h3cd276researchanddrugdevelopment AT jianronglu newfrontiersinimmunecheckpointb7h3cd276researchanddrugdevelopment AT øysteinfodstad newfrontiersinimmunecheckpointb7h3cd276researchanddrugdevelopment AT mingtan newfrontiersinimmunecheckpointb7h3cd276researchanddrugdevelopment |